Global Capecitabine Market Overview:
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment that reduces or prevents the progression of cancer cells. This drug is used for the treatment of cancers such as colorectal cancer, breast cancer, and gastric cancer. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows the growth of tumor tissue. Some of the key players profiled in the study are Dr Reddy Laboratories Ltd (India), Fresenius SE & Co. KGaA (Germany), Cipla Inc. (India), Genentech, Inc. (United States), F. Hoffmann-La Roche (Switzerland), Sandoz (Germany), Ranbaxy Laboratories Ltd. (India), Zentiva N.V. (Czechia), Teva Pharma B.V. (Netherlands) and Accord Healthcare Ltd. (India).
On the basis of geography, the market of Capecitabine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Formulation, the sub-segment i.e. Tablets will boost the Capecitabine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Geriatric Population
- Rise in Healthcare Expenditure and an Increase in Investment in Cancer Treatment or Assisted Programs by Governments
- Availability of Generic Drugs and Patent Expiration of Branded Drugs
- Stringent Government Regulations Related to the Safety
- High Cost of Capecitabine
- Huge Investment in R&D in Development of Drugs by Major Market Players
- Growing Health Care Industry
- Lack of Awareness among the Consumers
Major Market Developments:
In April 2019, the Emcure Pharmaceutical (India) Company has launched generic breast cancer medicine, which is used to treat HER 2 negative patients. Hence, it will benefit the increased product portfolio of the company in the future.
According to the National Cancer Institute around 135,430 people are estimated to suffer from colon and rectum cancer and 50,260 people died of colon and rectum cancer in 2017.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of a competitive advantage through combined collaborations.
Manufacturers of Capecitabine, Suppliers of Capecitabine, Wholesalers, Distributors and Retailers of Capecitabine, Healthcare Industry, Research Institutes, Governmental Bodies, Market Research Firms and Others
Major Objectives Focused through this Study
To define, describe, and forecast the Global Capecitabine market on the basis of product [500 mg and 150 mg] , application [Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer and Others], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Capecitabine market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Capecitabine industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Roche Holding AG (Switzerland), Mylan (United States), Hikma Pharmaceuticals (United Kingdom), Reliance Group (India) and Hetero (India).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Capecitabine market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.